Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» ICER
ICER
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
Yahoo/Reuters
Vertex Pharmaceutials
CRISPR Therapeutics
gene therapy
sickle cell disease
ICER
Flag link:
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Flag link:
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Stat
Biogen
Eisai
Alzheimer's disease
drug pricing
ICER
lecanemab
Flag link:
Aligning drug prices with ICER estimates could save tens of billions of dollars — JAMA paper
Aligning drug prices with ICER estimates could save tens of billions of dollars — JAMA paper
Endpoints
ICER
Inflation Reduction Act
drug pricing
Flag link:
On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega
On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega
Fierce Pharma
ICER
drug pricing
Bausch Health
Xifaxan
JNJ
Invega
Flag link:
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
Flag link:
ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab
ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab
Endpoints
ICER
MS
multiple sclerosis
drug pricing
ublituximab
TG Therapeutics
Flag link:
ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag
ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag
BioSpace
hemophilia
gene therapy
ICER
Biomarin
Chugai
Roche
CSL Behring
Flag link:
Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Endpoints
Vivus
Qsymia
weight loss
ICER
Novo Nordisk
Saxenda
Wegovy
Flag link:
Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care
Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care
Endpoints
Bluebird Bio
ICER
gene therapy
FDA
beti-cel
Flag link:
ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal
ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal
Fierce Pharma
ICER
Pfizer
Paxlovid
Merck
Ridgeback Biotherapeutics
molnupiravir
COVID-19
Flag link:
ICER says bluebird bio’s $2.1m gene therapy is cost-effective
ICER says bluebird bio’s $2.1m gene therapy is cost-effective
Pharmaforum
Bluebird Bio
ICER
beti-cel
FDA
Flag link:
A rarity for ICER: Cost watchdog says Covid-19 therapeutics appropriately priced in the US
A rarity for ICER: Cost watchdog says Covid-19 therapeutics appropriately priced in the US
Endpoints
ICER
drug pricing
COVID-19
Flag link:
FDA delays its decision on Bristol Myers' $13B heart drug another three months
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Bristol Myers Squibb
mavacamten
ICER
FDA
Flag link:
FDA delays its decision on Bristol Myers' $13B heart drug another three months
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Bristol Myers Squibb
FDA
ICER
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
ICER: Unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past
ICER: Unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past
Endpoints
ICER
drug pricing
Humira
AbbVie
Flag link:
Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
Fierce Pharma
Biogen
Aduhelm
ICER
Flag link:
ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits
ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits
Endpoints
Biogen
ICER
Aduhelm
Alzheimer's disease
drug pricing
Flag link:
Good pharma citizenship is more than tree hugging. ESG needs drug pricing input, analysts say
Good pharma citizenship is more than tree hugging. ESG needs drug pricing input, analysts say
Fierce Pharma
ICER
drug pricing
corporate citizenship
Flag link:
Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?
Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?
Endpoints
Biogen
aducanumab
Alzheimer's disease
drug pricing
ICER
Flag link:
Pages
1
2
3
4
next ›
last »